Genmab — Maj 2024
-
-
- bying cheep stocks, 2) get ahead of competition, 3) if this works broadly in many solid tumours they probably need BP to carry this though and deal could be done based on this study with more than a 1000 patients. This is of cause very speculative
- bying cheep stocks, 2) get ahead of competition, 3) if this works broadly in many solid tumours they probably need BP to carry this though and deal could be done based on this study with more than a 1000 patients. This is of cause very speculative
-
Det er uetisk at udvide et forsøg hvis der ikke er effekt ! Det er open lable, så de har adgang til data og kan derved havde begrundet udvidelsen. Rigshospitalet, Vejle og Herlev er med, findes der ikke noget anekdotisk herfra ?Hvad end de finder så er der da statistisk power i forsøget.
-
Data fra et større studie med Pembrolizumab og Chemo i NSCLC. Meget dårlig 5 års prognose. https://ascopubs.org/doi/10.1200/JCO.22.01990 Så må vi se frem til yderligere data på 1042.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind